Yuki Yamaguchi

ヤマグチユウキ | Yuki Yamaguchi

Affiliation and department：
Job title： Professor
Homepage URL (1)： http://yamaguchi.bio.titech.ac.jp/

Research field (3)： Cell biology , Molecular biology , Functional biochemistry

Research theme for competitive and other funds (13)：

2020 - 2023 Elucidation of the selection mechanism of transcription termination and polyadenylation sites by using novel proteomic approach
2020 - 2023 ミトコンドリア病細胞死阻止機構の解明と創薬
2017 - 2020 Search for novel modulators of cereblon, the target of thalidomide that regulates neural stem cell proliferation and deifferentiation
2012 - 2017 Promotion of the Transcription Cycle Area
2012 - 2017 Elucidation of control mechanisms of transcriptional checkpoint during Pol II elongation, termination, and recycle

Show all

Papers (140)：

Takumi Ito, Tomoko Asatsuma-Okumura, Akinori Endo, Junichi Yamamoto, Yoshiko Iwai, Yuki Yamaguchi, Mikihiko Naito, Hiroshi Handa, Yasushi Saeki. ZNF276 and WIZ are CRBN neosubstrates involved in the anti-angiogenic activity of thalidomide and immunomodulatory drugs. 2023
Noriyuki Azuma, Tadashi Yokoi, Taku Tanaka, Emiko Matsuzaka, Yuki Saida, Sachiko Nishina, Miho Terao, Shuji Takada, Maki Fukami, Kohji Okamura, et al. Integrator complex subunit 15 controls mRNA splicing and is critical for eye development. Human Molecular Genetics. 2023
Junichi Yamamoto, Tomoko Asatsuma-Okumura, Takumi Ito, Yuki Yamaguchi, Hiroshi H, a. History of IMiDs and Protein Degradation as a Pharmacological Modality. 2022
Junichi Yamamoto, Takumi Ito, Yuki Yamaguchi, Hiroshi Handa. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders. Chemical Society Reviews. 2022. 51. 15. 6234-6250
Hidefumi Suzuki, Ryota Abe, Miho Shimada, Tomonori Hirose, Hiroko Hirose, Keisuke Noguchi, Yoko Ike, Nanami Yasui, Kazuki Furugori, Yuki Yamaguchi, et al. The 3' Pol II pausing at replication-dependent histone genes is regulated by Mediator through Cajal bodies' association with histone locus bodies. Nature communications. 2022. 13. 1. 2905-2905

ｍore...

MISC (21)：

朝妻知子, 伊藤拓水, 山口雄輝, 半田宏. Identification of CRL4^CRBN neosubstrates involved in thalidomide teratogenicity. 日本農芸化学会大会講演要旨集(Web). 2021. 2021
野口慶介, 鈴木秀文, 阿部竜太, 池陽子, 井野洋子, 木村弥生, 梁明秀, 山口雄輝, 高橋秀尚. 新規のビオチン標識手法による核内構造体カハールボディ構成因子の網羅的解析. 日本分子生物学会年会プログラム・要旨集(Web). 2020. 43rd
山口雄輝. 転写反応の生化学. 生体の科学. 2017. vol. 68
鈴木秀文, 前田亮, 木村宏, 浦聖恵, 田村隆明, 山口雄輝. DNA損傷応答における転写抑制メカニズムとその生理的意義の解析. 日本生化学会大会(Web). 2017. 90th
高橋秀尚, 柴田美音, 瀧川一学, 渡部昌, 築山忠維, 山本淳一, 山口雄輝, 藤井聡, 飯田緑, RANJAN Amol, et al. メディエーター複合体による転写終結制御機構. 日本生化学会大会(Web). 2017. 90th. ROMBUNNO.4P2T15-06(3P-0635) (WEB ONLY)-0635)]

ｍore...

Patents (3)：

Books (16)：

ｍore...

Lectures and oral presentations (72)：

タンパク質コード遺伝子の3'末端プロセシングにおけるポリ(A)付加サイト選択の作用機序の解明
(第37回染色体ワークショップ・第18回核ダイナミクス研究会 2019)
Pol IIの転写終結部位を制御する分子機構
(第42回日本分子生物学会年会 2019)
E3ユビキチンリガーゼを標的とした創薬の新展開
(東工大創薬ゲノムシンポジウム 2019)
抗てんかん薬ゾニサミド、バルプロ酸の分子ターゲット探索とプテリジン代謝への影響
(第33回日本プテリジン研究会 2019)
Comprehensive identification of proximal proteins by in situ biotinylation through a specific antibody: toward proteomic analysis of liquid droplets
(2019)

ｍore...

Education (2)：

1995 - 1999 Tokyo Institute of Technology Graduate School of Bioscience and Biotechnology Department of Biotechnology
- 1995 Tokyo Institute of Technology School of Bioscience and Biotechnology

Professional career (1)：

Work history (10)：

2016/04 - 現在 Tokyo Institute of Technology School of Life Science and Technology Professor
2014/10 - 2022/03 Tokyo Medical University Chemical Biology Laboratory Visiting Professor
2013/07 - 2016/03 Tokyo Institute of Technology Graduate School of Bioscience and Biotechnology Professor
2010/10 - 2014/03 Japan Science and Technology Agency PRESTO Researcher
2009/01 - 2013/06 Tokyo Institute of Technology Graduate School of Bioscience and Biotechnology Associate Professor

Show all

Awards (5)：

Association Membership(s) (2)：

The Molecular Biology Society of Japan , 日本分子生物学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page